📊 BJDX Key Takeaways
Investment Thesis
Bluejay Diagnostics is a pre-revenue stage medical device company with severe operational losses and significant cash burn despite minimal revenue generation. The company is consuming approximately $6.1M annually in operating cash while generating only $249K in revenue, indicating an unproven business model with no clear path to profitability in the near term.
BJDX Strengths
- Strong liquidity position with $5.2M cash and 4.88x current ratio provides runway for operations
- Revenue growth of 167.8% YoY shows early commercial traction and market acceptance of products
- Zero long-term debt and 0.00x debt-to-equity ratio eliminates financial leverage risk
BJDX Risks
- Severe operating losses of $7.0M against $249K revenue indicates business model not yet viable at scale
- Negative free cash flow of $6.2M annually will exhaust current cash reserves within approximately 10 months without additional funding
- Profitability metrics show negative operating margin of -2791.9% and negative ROE of -114.6%, with no evidence of improvement trajectory
- No insider buying activity in last 90 days suggests lack of confidence from management
- Operating cash burn rate ($6.1M) far exceeds capital expenditure ($173.7K), indicating cash consumed by operations rather than growth investments
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate to assess runway sustainability
- Revenue growth acceleration and gross margin expansion to evaluate path to profitability
- Working capital changes and cash position to determine when additional financing becomes necessary
BJDX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.88x current ratio provides a solid financial cushion.
BJDX Profitability Ratios
BJDX vs Healthcare Sector
How Bluejay Diagnostics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BJDX Balance Sheet & Liquidity
BJDX 5-Year Financial Trend
5-Year Trend Summary: Bluejay Diagnostics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-456.75 indicates the company is currently unprofitable.
BJDX Growth Metrics (YoY)
BJDX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $249.0K | -$1.9M | $-2.08 |
| Q2 2023 | $249.0K | -$1.9M | $-2.00 |
| Q3 2022 | $249.0K | -$194.2K | $-0.11 |
| Q2 2022 | $249.0K | -$194.2K | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BJDX Capital Allocation
BJDX SEC Filings
Access official SEC EDGAR filings for Bluejay Diagnostics, Inc. (CIK: 0001704287)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BJDX
What is the AI rating for BJDX?
Bluejay Diagnostics, Inc. (BJDX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BJDX's key strengths?
Strong liquidity position with $5.2M cash and 4.88x current ratio provides runway for operations. Revenue growth of 167.8% YoY shows early commercial traction and market acceptance of products.
What are the risks of investing in BJDX?
Severe operating losses of $7.0M against $249K revenue indicates business model not yet viable at scale. Negative free cash flow of $6.2M annually will exhaust current cash reserves within approximately 10 months without additional funding.
What is BJDX's revenue and growth?
Bluejay Diagnostics, Inc. reported revenue of $249.0K.
Does BJDX pay dividends?
Bluejay Diagnostics, Inc. does not currently pay dividends.
Where can I find BJDX SEC filings?
Official SEC filings for Bluejay Diagnostics, Inc. (CIK: 0001704287) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BJDX's EPS?
Bluejay Diagnostics, Inc. has a diluted EPS of $-15.25.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.